Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Centogene receives Nasdaq delisting notice for non-compliance with market value requirement.

flag Centogene, a life sciences firm focusing on rare and neurodegenerative diseases, received a notice of delisting from Nasdaq due to non-compliance with the $15m Market Value of Publicly Held Shares requirement. flag The company plans to request a hearing to address the issue and prevent suspension or delisting. flag Despite the notice, Centogene will continue working with strategic partners to accelerate drug discovery, development, and commercialization.

3 Articles